US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Portfolio Pulse from Vandana Singh
Eli Lilly's Zepbound overtakes Novo Nordisk's Wegovy in new U.S. prescriptions for weight loss, marking a significant milestone since its launch in December. Despite Wegovy's lead in total prescriptions, Zepbound's surge highlights the competitive landscape in the GLP-1 drug market, expected to reach $105 billion by 2029. Additionally, Eli Lilly partners with Amazon Pharmacy for home delivery of select medications, enhancing access to treatments. Eli Lilly also combats counterfeit tirzepatide products through legal action.
March 18, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck's Keytruda is currently the world's top-selling prescription medicine. The growing GLP-1 market, led by drugs like Zepbound and Wegovy, is expected to challenge Keytruda's sales dominance.
While Keytruda currently holds the title of the world's top-selling prescription medicine, the expected growth of the GLP-1 market, particularly with drugs like Zepbound and Wegovy, could challenge its sales dominance in the future.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Novo Nordisk's Wegovy is overtaken by Eli Lilly's Zepbound in new U.S. prescriptions, but still leads in total weekly prescriptions. The GLP-1 market's growth potential remains significant for Novo Nordisk.
Despite the recent overtaking by Zepbound in new prescriptions, Wegovy's lead in total prescriptions and the expected growth of the GLP-1 market suggest a neutral to positive outlook for Novo Nordisk. The company's strong position in the GLP-1 market, expected to capture more than half of it, supports this view.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Amazon Pharmacy partners with Eli Lilly for home delivery of select medications, including Zepbound. This partnership could enhance Amazon Pharmacy's offerings and customer base.
The partnership with Eli Lilly allows Amazon Pharmacy to expand its medication delivery services, potentially attracting more customers seeking convenience. This strategic move could positively impact Amazon's position in the online pharmacy sector.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Eli Lilly's Zepbound surpasses Novo Nordisk's Wegovy in new U.S. prescriptions, indicating strong market demand and competitive advantage. Partnership with Amazon Pharmacy for medication delivery could further boost its market presence.
Zepbound's surpassing Wegovy in new prescriptions indicates strong market demand and potential for increased sales. The partnership with Amazon Pharmacy is likely to enhance accessibility and convenience for patients, potentially increasing sales further. Legal actions against counterfeit products protect the brand and product integrity.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90